While InterMune (ITMN.DL) was technically a loser today after falling 3%, this can only be seen as natural profit-taking after the stock detonated upward 170% in a single day earlier this week. The company has a first-in-class idiopathic pulmonary fibrosis drug that just aced its phase 3 trial and has solid market potential, possibly up to half a billion dollars in annual sales.
This being InterMune's only drug, Motley Fool health-care analyst David Williamson says in the following video that he agrees with analysts that this now looks like a takeover target. In the video, David looks ahead to the FDA approval process and discusses InterMune's chances of a favorable ruling, and discusses which companies would make the most likely suitors. This will definitely be a story to watch this year.
